Replimune Group, Inc.
$12.96
-$0.07 (-0.54%)
$12.71Day Range$13.19
Key Statistics
Market Cap
$1.23B
Shares Outstanding
94.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 20, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$13.10
Day High
$13.19
Day Low
$12.71
Volume
1.81M
VWAP
$12.93
Prev Close
$13.03
Transactions
--
Acc. Volume
--
About Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836465 employees500 UNICORN PARK, WOBURN, MA, 01801(781) 222-9600IPO Jul 20, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001737953
- Composite FIGI
- BBG00L8Z22R1
- Share Class FIGI
- BBG00L8Z22S0
- Ticker Root
- REPL
- SIC Code
- 2836
About Replimune Group, Inc. (REPL) Stock
Replimune Group, Inc. (REPL) closed the 2026-09-16 session at $12.96, down 0.54% versus the previous close (-0.07). The stock opened at $13.10 and traded between $12.71 and $13.19 during that session. Session trading volume was 1.8M shares. The volume-weighted average price (VWAP) is $12.93.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Replimune Group, Inc. has a market capitalization of $1.23 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. REPL is listed on the XNAS exchange. The company employs approximately 465 people. Replimune Group, Inc. is headquartered in WOBURN, MA. The recorded listing date is 2018-07-20.
On this page you can find market REPL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.